Advanced search
Publication Cover
Emerging Microbes & Infections Volume 5, 2016 - Issue 1
Submit an article Journal homepage
3,051
Views
38
CrossRef citations to date
0
Altmetric
Reviews

Vaccines and immunization strategies for dengue prevention

Yang LiuTsinghua-Peking Center for Life Sciences, School of Medicine, Tsinghua University, Beijing100084, China;School of Life Science, Tsinghua University, Beijing100084, China
,
Jianying LiuTsinghua-Peking Center for Life Sciences, School of Medicine, Tsinghua University, Beijing100084, China
&
Gong ChengTsinghua-Peking Center for Life Sciences, School of Medicine, Tsinghua University, Beijing100084, ChinaCorrespondence[email protected]
Pages 1-6 | Received 12 Feb 2016, Accepted 11 May 2016, Published online: 25 Jan 2019

  • RushAB.An account of the bilious remitting fever, as it appeared in Philadelphia in the summer and autumn of the year 1780.In: Rush AB (ed.).Medical Enquiries and Observations.Philadelphia: Prichard and Hall.1789; pp104–117.
  • Muñoz BernalJA.[Report on the epidemic that has suffered this city, commonly named dengue].Oficina del Gobierno y Capitanía General1828; 1:26.Spanish.
  • ShepardDS,UndurragaEA,HalasaYA.Economic and disease burden of dengue in Southeast Asia.PLoS Negl Trop Dis2013; 7:e2055.
  • RanjitS,KissoonN.Dengue hemorrhagic fever and shock syndromes.Pediatr Crit Care Med2011; 12:90–100.
  • GublerDJ.Dengue viruses.In: Mahy BW (ed.).Desk Encyclopedia of Human and Medical Virology.Boston: Academic Press.2010; pp372–382.
  • ReiterP.Yellow fever and dengue: a threat to Europe.Euro Surveill2010; 15:19509.
  • BhattS,GethingPW,BradyOJet al.The global distribution and burden of dengue.Nature2013; 496:504–507.
  • VaratharajA.Encephalitis in the clinical spectrum of dengue infection.Neurol India2010; 58:585–591.
  • WuJY,LunZR,JamesAA,ChenXG.Dengue fever in mainland China.Am J Trop Med Hyg2010; 83:664–671.
  • JinX,LeeM,ShuJ.Dengue fever in China: an emerging problem demands attention.Emerg Microbes Infect2015; 4:e3.
  • LaiS,HuangZ,ZhouHet al.The changing epidemiology of dengue in China, 1990-2014: a descriptive analysis of 25 years of nationwide surveillance data.BMC Med2015; 13:100.
  • Rigau-PérezJG,ClarkGG,GublerDJet al.Dengue and dengue haemorrhagic fever.Lancet1998; 352:971–977.
  • YoungPR,HilditchPA,BletchlyC,HalloranW.An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients.J Clin Microbiol2000; 38:1053–1057.
  • HalsteadSB.Pathogenesis of dengue: challenges to molecular biology.Science1988; 239:476–481.
  • ChengG,LiuY,WangP,XiaoX.Mosquito defense strategies against viral infection.Trends Parasitol2016; 32:177–186.
  • KraemerMU,SinkaME,DudaKAet al.The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus.Elife2015; 4:08347.
  • HadinegoroSR,Arredondo-GarcíaJL,CapedingMRet al.Efficacy and long-term safety of a dengue vaccine in regions of endemic disease.N Engl J Med2015; 373:1195–1206.
  • ConstenlaD,ClarkS.Financing dengue vaccine introduction in the Americas: challenges and opportunities.Expert Rev Vaccines2016; 15:547–559.
  • GuyB,BarrereB,MalinowskiCet al.From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.Vaccine2011; 29:7229–7241.
  • VlaychevaLA,ChambersTJ.Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread.J Virol2002; 76:6172–6184.
  • GuirakhooF,PugachevK,ZhangZet al.Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.J Virol2004; 78:4761–4775.
  • MorrisonD,LeggTJ,BillingsCWet al.A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.J Infect Dis2010; 201:370–377.
  • SabchareonA,WallaceD,SirivichayakulCet al.Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.Lancet2012; 380:1559–1567.
  • VillarL,DayanGH,Arredondo-GarcíaJLet al.Efficacy of a tetravalent dengue vaccine in children in Latin America.N Engl J Med2015; 372:113–123.
  • CapedingMR,TranNH,HadinegoroSRet al.Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observermasked, placebo-controlled trial.Lancet2014; 384:1358–1365.
  • HalsteadSB.Dengue vaccine development: a 75% solution?Lancet2012; 380:1535–1536.
  • YuY.Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities.Vaccine2010; 28:3635–3641.
  • MonathTP.Treatment of yellow fever.Antiviral Res2008; 78:116–124.
  • EckelsKH,DuboisDR,PutnakRet al.Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys.Am J Trop Med Hyg2003; 69:12–16.
  • BhamarapravatiN,SuteeY.Live attenuated tetravalent dengue vaccine.Vaccine2000; 18:44–47.
  • SabchareonA,LangJ,ChanthavanichPet al.Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.Am J Trop Med Hyg2002; 66:264–272.
  • SabchareonA,LangJ,ChanthavanichPet al.Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.Pediatr Infect Dis J2004; 23:99–109.
  • SanchezV,GimenezS,TomlinsonBet al.Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).Vaccine2006; 24:4914–4926.
  • ThomasSJ,EckelsKH,CarlettiIet al.A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.Am J Trop Med Hyg2013; 88:73–88.
  • WatanaveeradejV,GibbonsRV,SimasathienSet al.Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial.Am J Trop Med Hyg2014; 91:119–128.
  • DurbinAP,McArthurJ,MarronJAet al.The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.Hum Vaccine2006; 2:167–173.
  • DurbinAP,McArthurJH,MarronJAet al.rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.Hum Vaccine2006; 2:255–260.
  • DurbinAP,KirkpatrickBD,PierceKK,SchmidtAC,WhiteheadSS.Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.Vaccine2011; 29:7242–7250.
  • DurbinAP,KirkpatrickBD,PierceKKet al.A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naïve adults: a randomized,double-blind clinical trial.J Infect Dis2013; 207:957–965.
  • OsorioJE,HuangCY,KinneyRM,StinchcombDT.Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.Vaccine2011; 29:7251–7260.
  • OsorioJE,VelezID,ThomsonCet al.Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus -naïve healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.Lancet Infect Dis2014; 14:830–838.
  • SirivichayakulC,Barranco-SantanaEA,Esquilin-RiveraIet al.Safety and immunogenicity of a tetravalent dengue vaccine (TDV) in healthy children and adults in endemic regions: a randomized, placebo-controlled Phase 2 study.J Infect Dis2016; 213:1562–1572.
  • ClinicalTrials.govTDENV PIV and LAV Dengue Prime-boost Strategy.Maryland: WRAIR.2014.Available athttps://clinicaltrials.gov/ct2/show/NCT02239614?term=TDENV+PIV+and+LAV+dengue+prime-boost+strategy&rank=1(accessed 30 December 2015).
  • ClementsDE,CollerBA,LiebermanMMet al.Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.Vaccine2010; 28:2705–2715.
  • HermidaL,BernardoL,MartinJet al.A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.Vaccine2006; 24:3165–3171.
  • LengCH,LiuSJ,TsaiJPet al.A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity.Microbes Infect2009; 11:288–295.
  • ChenHW,LiuSJ,LiuHHet al.A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design.Vaccine2009; 27:1400–1409.
  • BlockOK,RodrigoWSI,QuinnMet al.A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.Vaccine2010; 28:8085–8094.
  • MidgleyCM,Bajwa-JosephM,VasanawathanaSet al.An in-depth analysis of original antigenic sin in dengue virus infection.J Virol2011; 85:410–421.
  • WilliamsKL,WahalaWM,OrozcoS,de SilvaAM,HarrisE.Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.Virology2012; 429:12–20.
  • CollerBA,ClementsDE,BettAJ,SagarSL,Ter MeulenJH.The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.Vaccine2011; 29:7267–7275.
  • RaviprakashK,PorterKR,KochelTJet al.Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques.J Gen Virol2000; 81:1659–1667.
  • RaviprakashK,MarquesE,EwingDet al.Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF.Virology2001; 290:74–82.
  • BlairPJ,KochelTJ,RaviprakashKet al.Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys.Vaccine2006; 24:1427–1432.
  • LuY,RaviprakashK,LeaoICet al.Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies.Vaccine2003; 21:2178–2189.
  • WhiteheadSS,BlaneyJE,DurbinAP,MurphyBR.Prospects for a dengue virus vaccine.Nat Rev Microbiol2007; 5:518–528.
  • ThomasSJ,EndyTP.Critical issues in dengue vaccine development.Curr Opin Infect Dis2011; 24:442–450.
  • AkeyDL,BrownWC,DuttaSet al.Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system.Science2014; 343:881–885.
  • HenchalEA,HenchalLS,SchlesingerJJ.Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus.J Gen Virol1988; 69:2101–2107.
  • SchlesingerJJ,BrandrissMW,WalshEE.Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus nonstructural glycoprotein NS1.J Gen Virol1987; 68:853–857.
  • AmorimJH,DinizMO,CaririFAet al.Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant.Vaccine2012; 30:837–845.
  • BeattyPR,Puerta-GuardoH,KillingbeckSSet al.Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination.Sci Transl Med2015; 7:304ra141.
  • ModhiranN,WattersonD,MullerDAet al.Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity.Sci Transl Med2015; 7:304ra142.
  • SrivastavaAK,PutnakJR,WarrenRL,Hoke JrCH.Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection.Vaccine1995; 13:1251–1258.
  • LuH,XuXF,GaoNet al.Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice.Mol Immunol2013; 54:109–114.
  • CostaSM,FreireMS,AlvesAM.DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus.Vaccine2006; 24:4562–4564.
  • WuSF,LiaoCL,LinYLet al.Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice.Vaccine2003; 21:3919–3929.
  • FalgoutB,BrayM,SchlesingerJJ,LaiCJ.Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis.J Virol1990; 64:4356–4363.
  • WanSW,LinCF,YehTMet al.Autoimmunity in dengue pathogenesis.J Formos Med Assoc2013; 112:3–11.
  • LinYS,YehTM,LinCFet al.Molecular mimicry between virus and host and its implications for dengue disease pathogenesis.Exp Biol Med2011; 236:515–523.
  • MiuraK,KeisterDB,MuratovaOVet al.Transmission-blocking activity nduced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.Malaria J2007; 6:107.
  • ChowdhuryDR,AngovE,KariukiT,KumarN.A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli.PLoS One2009; 4:e6352.
  • PalU,LiX,WangTet al.TROSPA, an Ixodes scapularis receptor for Borrelia burgdorferi.Cell2004; 119:457–468.
  • LabudaM,TrimnellAR,LičkováMet al.An antivector vaccine protects against a lethal vector-borne pathogen.PLoS Pathog2006; 2:e27.
  • HavlíkováS,RollerL,KočiJet al.Functional role of 64P, the candidate transmission-blocking vaccine antigen from the tick, Rhipicephalus appendiculatus.Int J Parasitol2009; 39:1485–1494.
  • PatesH,CurtisC.Mosquito behavior and vector control.Annu Rev Entomol2005; 50:53–70.
  • LiuY,LiuJ,PangXet al.The roles of direct recognition by animal lectins in antiviral immunity and viral pathogenesis.Molecules2015; 20:2272–2295.
  • LiuY,ZhangF,LiuJet al.Transmission-blocking antibodies against mosquito C-type lectins for dengue prevention.PLoS Pathog2014; 10:e1003931.
  • Londono-RenteriaB,TroupinA,ConwayMJet al.Dengue virus infection of Aedes aegypti requires a putative cysteine rich venom protein.PLoS Pathog2015; 11:e1005202.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.